Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 2008

View Archived Issues

IGF-I elevations last over one week after single injection of NNC-126-0083

Recent AstraZeneca patents describe new imaging agents

CNTO-328 demonstrates activity in ovarian cancer trial

New p38alpha MAPK inhibitors disclosed in recent Almirall patent

Recent Takeda patent reports new 5-HT2C receptor agonists for urinary incontinence

Diabetes candidate ARRY-403 to advance to clinical investigation

Ranbaxy submits IND in India to initiate phase I trials of respiratory inflammation candidate

Vernalis receives milestone payment from Servier under oncology drug program

Acusphere's Imagify to be reviewed at FDA Advisory Committee Meeting in December 2008

New agents for treating endocrine disorders divulged in recent patent literature

King Pharmaceuticals extends tender offer until November 2008 to acquire Alpharma

PharmAthene raises USD 13.1 million in strategic equity financing with Panacea Biotec

NVA-237 provides bronchodilation to COPD patients in phase II studies

Differin gel to be launched in Japan for topical treatment of acne vulgaris

Dr. Reddy's subsidiary launches EpiCeram skin barrier emulsion

Lisofylline to be studied in phase II trial to improve islet cell transplant outcomes

Omrix receives EMEA approval for Evicel liquid fibrin sealant

Pfizer launches Macugen for age-related macular degeneration in Japan

Acura and King present top-line results for Acurox in abuse liability

Neurogen reports results from phase II trials of aplindore in RLS and PD

Nile reports interim data from phase IIa CD-NP study in heart failure

TB Alliance and sanofi aventis enter collaboration for new TB drugs

MMRC initiates phase Ib study of elotuzumab in combination with Revlimid and dexamethasone

R&D highlights from the UBS Global Life Sciences Conference in New York: Orexigen Therapeutics

Overall survival and safety data on elesclomol reported

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...